Summary & Overview
HCPCS Level II J9010: Alemtuzumab Injection, 10 mg
HCPCS Level II code J9010 denotes a 10 mg injection of alemtuzumab, an oncology-focused monoclonal antibody administered via infusion. Nationally, this code is used in outpatient infusion centers and hospital outpatient departments to capture drug acquisition and administration for patients receiving targeted hematology-oncology therapy. Precise coding for high-cost biologic agents like alemtuzumab is important for claims processing, clinical documentation, and tracking utilization of specialty therapies.
Key payers discussed include Blue Cross Blue Shield and Cigna Health. The publication covers payer coverage considerations, coding and billing context for infusion-based monoclonal antibodies, and how J9010 fits within related drug code groupings. Readers will find an overview of typical clinical indications tying the code to oncology and hematology practice, common service locations, and links to adjacent codes used for comparable monoclonal antibody injections.
Where input details are incomplete, the publication notes data limitations rather than inferring missing elements. The content is intended for billing managers, revenue cycle professionals, and clinicians involved in oncology drug administration who need a concise reference to the clinical and billing context of HCPCS Level II code J9010.
Billing Code Overview
HCPCS Level II code J9010 represents an injection of alemtuzumab, 10 mg, a monoclonal antibody therapy used in oncology and hematology care. The code applies to administration of the specified drug preparation and is associated with infusion-based treatment.
Service type: Oncology / Hematology (monoclonal antibody therapy)
Typical site of service: Infusion center or hospital outpatient setting (for example, POS 22).
Data not available in the input for additional billing line metadata.
Clinical & Coding Specifications
A patient with a hematologic or oncologic malignancy presents to an infusion center or hospital outpatient department for monoclonal antibody therapy. The ordering oncologist prescribes alemtuzumab dosed in 10 mg increments to treat or manage disease activity. On arrival, the patient undergoes intake triage (vital signs, allergy review, premedication assessment), venous access placement, and administration of alemtuzumab via intravenous infusion by an oncology-certified RN in a monitored infusion chair or curtained bay. Continuous monitoring for infusion reactions and hematologic or infectious complications occurs during and after the infusion per institutional protocols. Drug handling includes pharmacy preparation under aseptic technique, documentation of lot number and expiration, and recording of units administered and any portion discarded. Billing uses HCPCS Level II code J9010 to report alemtuzumab, 10 mg, with applicable modifiers for discarded drug (JW) or if a distinct procedural service is provided (59). Typical sites of service include infusion center or hospital outpatient (e.g., POS 22). Associated provider specialties include hematology/oncology and medical oncology clinicians responsible for prescribing and supervising therapy.
Modifiers:
-
JW: Drug amount discarded/not administered to any patient — Append when any portion of the dispensed alemtuzumab is discarded and not administered; document discarded amount and rationale per payor policy. -
59: Distinct Procedural Service — Append when the infusion or related service is distinct and separate from other services provided on the same day; support with documentation that the service is separate and unrelated to other procedures.
Provider Taxonomies:
-
207RH0003X— Hematology & Oncology Physician: Specialists who diagnose and manage hematologic and oncologic disorders and prescribe monoclonal antibody therapies. -
207RX0202X— Medical Oncology Physician: Physicians focused on systemic cancer therapy management, including ordering and oversight of infusional monoclonal antibodies. -
2084P0800X— Pediatric Hematology-Oncology Physician: Pediatric specialists who manage malignant and hematologic diseases in children and prescribe age-appropriate monoclonal antibody therapy.
Related Diagnoses:
-
C50.911— Malignant neoplasm of unspecified site of right female breastRelevance: Breast malignancy may be managed by systemic therapies including monoclonal antibodies when indicated; billing with
J9010reflects administration of a monoclonal antibody for an oncologic indication. -
C34.90— Malignant neoplasm of unspecified part of unspecified bronchus or lungRelevance: Lung cancer is a potential indication for systemic biologic therapies; associating this diagnosis supports medical necessity for infusional monoclonal antibody therapy.
-
C22.8— Malignant neoplasm of liver, primary, unspecified as to typeRelevance: Primary liver malignancies may receive systemic treatments; this diagnosis may appear on the claim when alemtuzumab is used in relevant oncologic protocols.
-
C56.9— Malignant neoplasm of unspecified ovaryRelevance: Ovarian cancer management can include systemic biologic agents; this diagnosis may be listed to justify administration of monoclonal antibody therapy.
-
C79.51— Secondary malignant neoplasm of boneRelevance: Metastatic bone involvement from a primary cancer often prompts systemic therapy; this secondary diagnosis may be reported with
J9010when treating metastatic disease.
Related Codes:
J9302— Injection, ofatumumab, 10 mg
Relation to primary code:
J9302is an alternative monoclonal antibody agent with a similar billing unit measure (10 mg) used in oncology/hematology. In clinical workflows,J9302may be billed instead ofJ9010when ofatumumab is the agent administered. These codes are commonly considered alternatives rather than billed together; do not report both for the same drug administration. Documentation must reflect the specific drug administered.
National Reimbursement Benchmarks
National mean rates for HCPCS Level II code J9010 show that BUCA (the average commercial benchmark) has a mean of $573.33, which is higher than Blue Cross Blue Shield’s mean of $480.23 and lower than Cigna Health’s mean of $787.08. Medicare mean is not provided in the input for direct comparison; where Medicare data is missing, state that Medicare data is not available in the input.
Rate dispersion (P75 minus P25) varies across payers. Blue Cross Blue Shield shows a wide dispersion driven by a low 25th percentile ($77.50) and a high 75th percentile ($663.00). Cigna Health is the tightest, with a small spread between the 25th ($783.50) and 75th ($793.66) percentiles. BUCA shows moderate dispersion (P75 $773.00 vs P25 $635.00). The table and chart below present the full breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.